{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:00:24Z","timestamp":1791198024985,"version":"4.1.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual incretin agonists have transformed the management of obesity and type 2 diabetes and are rapidly reshaping the population seeking aesthetic surgery. By producing double-digit percentage weight loss, these agents expand eligibility for elective procedures while generating new patterns of skin redundancy, soft-tissue laxity, and facial volume depletion that drive demand for body contouring and facial rejuvenation. At the same time, incretin therapy introduces distinct perioperative considerations: delayed gastric emptying with possible pulmonary aspiration in symptomatic patients, gastrointestinal adverse effects that peak during dose escalation, loss of lean mass with rapid weight reduction, nutritional inadequacy during profound appetite suppression, and frequent weight regain after drug discontinuation, which threatens the durability of surgical results. This mini-review synthesizes current evidence on the mechanisms of GLP-1 RAs relevant to the reconstructive surgical patient, summarizes the evolving guidance from anesthesia societies, moving from blanket preoperative withholding to individualized risk stratification, reviews emerging outcome data on body contouring in GLP-1 RA users, and discusses body composition, sarcopenia risk, and nutritional optimization. We propose a pragmatic framework, anchored in weight stability and symptom burden, for timing elective aesthetic procedures relative to GLP-1 RA initiation, escalation, and maintenance, along with a multidisciplinary perioperative algorithm that links the endocrinologist, plastic surgeon, and anesthesiologist. As incretin-based pharmacotherapy expands globally, coordinated endocrine\u2013surgical\u2013anesthetic care will be essential to maximize safety, functional recovery, and patient satisfaction in the GLP-1 era.<\/jats:p>","DOI":"10.3389\/fendo.2026.1969433","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:08:11Z","timestamp":1791194891000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Glucagon-like peptide-1 receptor agonists and aesthetic surgery: perioperative safety, timing, durability and body composition"],"prefix":"10.3389","volume":"17","author":[{"given":"Richa","family":"Chaturvedi","sequence":"first","affiliation":[{"name":"Advance Center for Obesity, Diabetes and Endocrinology (ACODE), Indraprastha Apollo Hospital","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuldeep","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Aesthetic, Plastic and Reconstructive Surgery, Indraprastha Apollo Hospital","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rameshwari R.","family":"Chakole","sequence":"additional","affiliation":[{"name":"Advance Center for Obesity, Diabetes and Endocrinology (ACODE), Indraprastha Apollo Hospital","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhupesh K.","family":"Yadav","sequence":"additional","affiliation":[{"name":"Advance Center for Obesity, Diabetes and Endocrinology (ACODE), Indraprastha Apollo Hospital","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juli","family":"Dhameliya","sequence":"additional","affiliation":[{"name":"Advance Center for Obesity, Diabetes and Endocrinology (ACODE), Indraprastha Apollo Hospital","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepali","family":"Joshi","sequence":"additional","affiliation":[{"name":"Advance Center for Obesity, Diabetes and Endocrinology (ACODE), Indraprastha Apollo Hospital","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"B3","volume-title":"KFF Health Tracking Poll may 2024: The Public\u2019s Use and Views of GLP-1 Drugs","author":"Montero","year":"2024"},{"key":"B4","volume-title":"2024 ASPS Procedural Statistics Release","year":"2025"},{"key":"B5","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.soard.2019.10.025","article-title":"Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures \u2013 2019 update: cosponsored by American Association of Clinical Endocrinologists\/American College of Endocrinology, The Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists","volume":"16","author":"Mechanick","year":"2020","journal-title":"Surg For Obes Related Dis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: Their role in health and disease","volume":"20","author":"Nauck","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/clinem\/dgae719","article-title":"Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide","volume":"110","author":"Jalleh","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1177\/0022034509359125","article-title":"Factors affecting wound healing","volume":"89","author":"Guo","year":"2010","journal-title":"J Dent Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1017\/ice.2015.249","article-title":"Diabetes and risk of surgical site infection: A systematic review and meta-analysis","volume":"37","author":"Martin","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajcnut.2025.04.023","article-title":"Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society","volume":"122","author":"Mozaffarian","year":"2025","journal-title":"Am J Clin Nutr"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/asjof\/ojaf056","article-title":"Ozempic face\u201d in plastic surgery: A systematic review of the literature on GLP-1 receptor agonist mediated weight loss and analysis of public perceptions","volume":"7","author":"Daneshgaran","year":"2025","journal-title":"Aesthet Surg J Open Forum"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinane.2023.111091","article-title":"Relationship between perioperative semaglutide use and residual gastric content: A retrospective analysis of patients undergoing elective upper endoscopy","volume":"87","author":"Silveira","year":"2023","journal-title":"J Clin Anesth"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s12630-023-02549-5","article-title":"Influence of semaglutide use on the presence of residual gastric solids on gastric ultrasound: A prospective observational study in volunteers without obesity recently started on semaglutide","volume":"70","author":"Sherwin","year":"2023","journal-title":"Can J Anesthesia\/Journal canadien d\u2019anesth\u00e9sie"},{"key":"B14","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1001\/jamasurg.2024.0111","article-title":"Glucagon-like peptide-1 receptor agonist use and residual gastric content before anesthesia","volume":"159","author":"Sen","year":"2024","journal-title":"JAMA Surg"},{"key":"B15","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1053\/j.gastro.2024.03.015","article-title":"Increased risk of aspiration pneumonia associated with endoscopic procedures among patients with glucagon-like peptide 1 receptor agonist use","volume":"167","author":"Yeo","year":"2024","journal-title":"Gastroenterology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1001\/jama.2024.5003","article-title":"Preoperative GLP-1 receptor agonist use and risk of postoperative respiratory complications","volume":"331","author":"Dixit","year":"2024","journal-title":"JAMA"},{"key":"B17","volume-title":"American Society of Anesthesiologists Consensus-Based Guidance on Preoperative Management of Patients (Adults and Children) on Glucagon-Like Peptide-1 Receptor Agonists","author":"Joshi","year":"2023"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0000000000004776","article-title":"ASA consensus-based guidance on preoperative management of patients on glucagon-like peptide-1 receptor agonists","volume":"140","author":"Ushakumari","year":"2024","journal-title":"Anesthesiology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.10.003","article-title":"Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period","volume":"23","author":"Kindel","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.bja.2025.04.001","article-title":"Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement","volume":"135","author":"Oprea","year":"2025","journal-title":"Br J Anaesth"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1177\/0310057X251355288","article-title":"2025 ADS\/ANZCA\/GESA\/NACOS clinical practice recommendations on the peri-procedural use of GLP-1\/GIP receptor agonists","volume":"53","author":"Hocking","year":"2025","journal-title":"Anaesth Intensive Care"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.11.002","article-title":"AGA rapid clinical practice update on the management of patients taking GLP-1 receptor agonists prior to endoscopy: Communication","volume":"22","author":"Hashash","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S008","article-title":"8. Obesity and weight management for the prevention and treatment of type 2 diabetes: Standards of care in diabetes\u20132025","volume":"48","author":"ElSayed","year":"2025","journal-title":"Diabetes Care"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00266-026-05978-x","article-title":"Impact of preoperative semaglutide discontinuation timing on postoperative outcomes in aesthetic abdominoplasty: A retrospective comparative study","volume":"50","author":"Bruno","year":"2026","journal-title":"Aesthetic Plast Surg"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/obr.12143","article-title":"Weight loss composition is one\u2010fourth fat\u2010free mass: A critical review and critique of this widely cited rule","volume":"15","author":"Heymsfield","year":"2014","journal-title":"Obes Rev"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16275","article-title":"Body composition changes during weight reduction with tirzepatide in the SURMOUNT \u20101 study of adults with obesity or overweight","volume":"27","author":"Look","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00272-9","article-title":"Muscle matters: The effects of medically induced weight loss on skeletal muscle","volume":"12","author":"Prado","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Sarcopenia: Revised European consensus on definition and diagnosis","volume":"48","author":"Cruz-Jentoft","year":"2019","journal-title":"Age Ageing"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3945\/an.116.014506","article-title":"Preserving healthy muscle during weight loss","volume":"8","author":"Cava","year":"2017","journal-title":"Adv Nutr"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/nu10040423","article-title":"Resistance training prevents muscle loss induced by caloric restriction in obese elderly individuals: A systematic review and meta-analysis","volume":"10","author":"Sardeli","year":"2018","journal-title":"Nutrients"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028198","article-title":"Healthy weight loss maintenance with exercise, liraglutide, or both combined","volume":"384","author":"Lundgren","year":"2021","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04204-0","article-title":"Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: A randomized phase 2 trial","volume":"32","author":"Heymsfield","year":"2026","journal-title":"Nat Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjaf029","article-title":"Postoperative outcomes in body contouring procedures following glucagon-like peptide-1 receptor agonist use: A 10-year analysis","volume":"45","author":"Liang","year":"2025","journal-title":"Aesthet Surg J"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00266-025-05015-3","article-title":"GLP-1 agonists in aesthetic surgery: Implications for perioperative outcomes and body contouring procedures","volume":"49","author":"Albanese","year":"2025","journal-title":"Aesthetic Plast Surg"},{"key":"B35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s44452-026-00024-w","article-title":"Safety of GLP-1 receptor agonists in body contouring surgery: A systematic review and meta-analysis","volume":"2","author":"Collaco","year":"2026","journal-title":"BMC Plast Reconstructive Surg"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"B38","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.57349","article-title":"Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity","volume":"8","author":"Rodriguez","year":"2025","journal-title":"JAMA Netw Open"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple\u2013hormone-receptor agonist retatrutide for obesity \u2014 A phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502082","article-title":"Cagrilintide\u2013semaglutide in adults with overweight or obesity and type 2 diabetes","volume":"393","author":"Davies","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1969433\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:08:12Z","timestamp":1791194892000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1969433\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":41,"alternative-id":["10.3389\/fendo.2026.1969433"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1969433","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"article-number":"1969433"}}